<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537107</url>
  </required_header>
  <id_info>
    <org_study_id>MC1111</org_study_id>
    <secondary_id>NCI-2011-03809</secondary_id>
    <nct_id>NCT01537107</nct_id>
  </id_info>
  <brief_title>Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery</brief_title>
  <official_title>Phase I Trial of The Combination of Vismodegib and Sirolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best dose of sirolimus when given&#xD;
      together with vismodegib in treating patients with solid tumors or pancreatic cancer that is&#xD;
      metastatic or cannot be removed by surgery. Sirolimus and vismodegib may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximally tolerated dose (MTD) of the combination of vismodegib and&#xD;
      sirolimus in unresectable solid tumors. (Cohort I)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the adverse event profile associated with this treatment combination.&#xD;
&#xD;
      II. To describe the tumor responses to treatment combination.&#xD;
&#xD;
      CORRELATIVE OBJECTIVES:&#xD;
&#xD;
      I. To assess the effect of the sirolimus and vismodegib combination on selected biomarkers in&#xD;
      tumor biopsies of patients with metastatic pancreatic cancer.&#xD;
&#xD;
      II. To assess the effect of the combination of vismodegib and sirolimus on fludeoxyglucose F&#xD;
      18 (F18-FDG) positron emission tomography (PET) or PET/computed tomography (CT) imaging in&#xD;
      Cohort II (MTD) patients with metastatic pancreatic cancer.&#xD;
&#xD;
      III. To study the association of clinical (toxicity and/or tumor response or activity) with&#xD;
      the biologic (pharmacodynamic) results obtained by examining tissue biopsies and PET or&#xD;
      PET/CT imaging from the same patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of sirolimus.&#xD;
&#xD;
      Patients receive sirolimus orally (PO) once daily (QD) and vismodegib PO QD on days 1-28.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2012</start_date>
  <completion_date type="Actual">June 27, 2018</completion_date>
  <primary_completion_date type="Actual">June 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD (Cohort I) ) and toxicity profile of combination of vismodegib plus sirolimus every 28 days.</measure>
    <time_frame>120 days</time_frame>
    <description>MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients). DLT will be defined as a course 1 adverse event (Common Terminology Criteria for Adverse Events [CTCAE] v 4.0) attributed (definitely, probably, or possibly) to the study treatment. MTD will be examined in an exploratory and hypothesis generating fashion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) profile in terms of the number and severity of all adverse events (overall, by dose-level, and by tumor group) at baseline, at each dose level and at 30 days after completion of study treatment</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effect of molecularly targeted agents non-invasively by F18-FDG PET or PET/CT (Cohort II)</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Acinar Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Duct Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>GDC-0449</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>Rapamune</other_name>
    <other_name>rapamycin</other_name>
    <other_name>RAPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COHORT I (DOSE ESCALATION): histologic proof of cancer that is now unresectable, not&#xD;
             amenable to any other standard therapies, or patient refuses standard therapy&#xD;
&#xD;
          -  COHORT II (MTD): metastatic adenocarcinoma of the pancreas and tumor amenable to&#xD;
             biopsies; prior systemic treatment for metastatic disease is allowed&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) =&gt; 1500/uL&#xD;
&#xD;
          -  Platelet &gt;= 100,000/uL&#xD;
&#xD;
          -  Total bilirubin =&lt; upper limit of normal (ULN) Aspartate aminotransferase (AST) (serum&#xD;
             glutamic oxaloacetic transaminase [SGOT]) =&lt; 3 x ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR) &lt; 1.25 x ULN (Cohort II&#xD;
             [MTD] only)&#xD;
&#xD;
          -  Cholesterol &lt; Common Terminology Criteria for Adverse Events (CTCAE) grade 3&#xD;
&#xD;
          -  Triglycerides &lt; CTCAE grade 2&#xD;
&#xD;
          -  Magnesium &gt;= lower limit of normal (LLN) and =&lt; ULN&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Willing to return to Mayo Clinic for follow up&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Cohort II (MTD) only - Translational Research: Willing to provide the biologic&#xD;
             specimens as required by the protocol; Note: this is part of the mandatory&#xD;
             translational research component&#xD;
&#xD;
          -  Women of childbearing potential only: Negative serum pregnancy test done =&lt; 7 days&#xD;
             prior to registration; NOTE: female subjects who are pregnant or nursing are excluded&#xD;
             from this study; there is no specific mitigation strategy for vismodegib toxicity;&#xD;
             however, male patients should be made aware of it during the consent process; although&#xD;
             this effect is expected to be reversible with discontinuation of dosing, long-term&#xD;
             effects on male fertility cannot be excluded at this time&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2&#xD;
&#xD;
          -  Able to swallow or have medication administered through a G-tube and absorb the&#xD;
             medication&#xD;
&#xD;
          -  Participant agrees to use acceptable form of contraception during the study and for up&#xD;
             to 7 months after last study drug dose&#xD;
&#xD;
          -  Acceptable forms of contraception:&#xD;
&#xD;
               -  Latex condom (always used with spermicide)&#xD;
&#xD;
               -  Diaphragm (always used with spermicide)&#xD;
&#xD;
               -  Cervical cap (always used with spermicide)&#xD;
&#xD;
          -  Acceptable forms of secondary contraception, when used along with a barrier method:&#xD;
&#xD;
               -  Hormonal contraception methods, including pills, patches, rings, or injections&#xD;
                  except progestin-only containing pills (i.e. &quot;Mini-pill&quot;)&#xD;
&#xD;
               -  Tubal ligation&#xD;
&#xD;
               -  Partner's vasectomy&#xD;
&#xD;
               -  Intrauterine device (non-progesterone T)&#xD;
&#xD;
               -  Vaginal sponge (containing spermicide)&#xD;
&#xD;
          -  Other acceptable forms:&#xD;
&#xD;
               -  100% commitment to abstinence&#xD;
&#xD;
          -  Unacceptable forms of contraception for women of childbearing potential:&#xD;
&#xD;
               -  Oral contraception containing progestins only&#xD;
&#xD;
               -  Intrauterine device (IUD) progesterone T&#xD;
&#xD;
               -  Female condom&#xD;
&#xD;
               -  Natural family planning (rhythm method) or breastfeeding&#xD;
&#xD;
               -  Fertility awareness&#xD;
&#xD;
               -  Withdrawal&#xD;
&#xD;
               -  Cervical shield&#xD;
&#xD;
          -  Willing not to smoke&#xD;
&#xD;
          -  Willing to complete a pill diary each day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COHORT I (DOSE ESCALATION): Known standard therapy for the patient's disease that is&#xD;
             potentially curative or definitely capable of extending life expectancy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, diabetes mellitus or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Any of the following prior therapies:&#xD;
&#xD;
               -  Chemotherapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Mitomycin C/nitrosoureas =&lt; 6 weeks prior to registration&#xD;
&#xD;
               -  Immunotherapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Biologic therapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Radiation therapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Radiation to &gt; 25% of bone marrow&#xD;
&#xD;
          -  Failure to fully recover from acute, reversible effects of prior chemotherapy&#xD;
             regardless of interval since last treatment&#xD;
&#xD;
          -  New York Heart Association classification III or IV&#xD;
&#xD;
          -  Uncontrolled Seizure Disorder&#xD;
&#xD;
          -  Central nervous system (CNS) metastases if not stable for at least 2-3 months based on&#xD;
             imaging, clinical assessment, use of steroids, or seizure disorder&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  This study involves an investigational agent whose genotoxic, mutagenic and&#xD;
                  teratogenic effects on the developing fetus and newborn are unknown&#xD;
&#xD;
          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy&#xD;
             considered investigational (utilized for a non-Food and Drug Administration&#xD;
             [FDA]-approved indication and in the context of a research investigation) or receiving&#xD;
             any other investigational agent which would be considered as a treatment for the&#xD;
             primary neoplasm&#xD;
&#xD;
          -  Receiving any medications or substances that are strong or moderate inhibitors of&#xD;
             cytochrome P450 3A4 (CPY450 3A4); use of the following strong or moderate inhibitors&#xD;
             are prohibited:&#xD;
&#xD;
          -  Strong Inhibitors of CYP3A4: Indinavir, Nelfinavir, Ritonavir, Clarithromycin,&#xD;
             Itraconazole, Ketoconazole, Nefazodone, Saquinavir, Telithromycin&#xD;
&#xD;
               -  Moderate Inhibitors of CYP3A4: Aprepitant, Erythromycin, Fluconazole, Grapefruit&#xD;
                  juice, Verapamil, Diltiazem&#xD;
&#xD;
          -  Receiving any medications or substances that are inducers of CYP450 3A4&#xD;
&#xD;
               -  Inducers of CYP3A4: Efavirenz, Nevirapine, Carbamazepine, Modafinil,&#xD;
                  Phenobarbital, Phenytoin, Pioglitazone, Rifabutin, Rifampin, St. John's wort&#xD;
&#xD;
          -  Receiving any medications or substances that are strong or moderate inhibitors of&#xD;
             CYP450 CYP2C8&#xD;
&#xD;
               -  Strong or Moderate Inhibitors of CYP2C8: Gemfibrozil, Trimethoprim&#xD;
&#xD;
          -  Receiving any medications or substances that are inducers of CYP450 2C8&#xD;
&#xD;
               -  Inducer of CYP2C8: Rifampin&#xD;
&#xD;
          -  Receiving any medications or substances that are strong or moderate inhibitors of&#xD;
             CYP450 CYP2C9&#xD;
&#xD;
               -  Strong or Moderate Inhibitors of CYP2C9: Fluconazole, Amiodarone&#xD;
&#xD;
          -  Receiving any medications or substances that are inducers of CYP450 2C9&#xD;
&#xD;
               -  Inducers of CYP2C9: Rifampin, Secobarbital&#xD;
&#xD;
          -  Immunocompromised patients (other than that related to the use of corticosteroids)&#xD;
             including patients receiving highly active antiretroviral therapy (HAART) treatment&#xD;
&#xD;
          -  Active other malignancy, excepting non-melanotic skin cancer or carcinoma-in situ&#xD;
             (e.g. of cervix, breast prostate); if there is a history of prior malignancy, they&#xD;
             must not be receiving other specific treatment (other than hormonal therapy) for their&#xD;
             cancer&#xD;
&#xD;
          -  History of myocardial infarction =&lt; 6 months, or congestive heart failure requiring&#xD;
             use of ongoing maintenance therapy for life-threatening ventricular arrhythmias&#xD;
&#xD;
          -  Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjogren's&#xD;
             syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp&#xD;
             examination using a vital dye (e.g., fluorescein, Bengal Rose), and/or an abnormal&#xD;
             corneal sensitivity test (Schirmer test or similar tear production test)&#xD;
&#xD;
          -  Prior therapy with a hedgehog inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Erlichman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Campus in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Campus in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Acinar Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

